Topic: Health

Scientists found that giving immunotherapy before surgery can greatly improve outcomes for certain colon cancer patients. In a new study, patients who received this treatment stayed cancer-free for almost three years.

Cancer Breakthrough: Immunotherapy Before Surgery Shows Promise

A recent clinical trial has shown that giving immunotherapy to colon cancer patients before surgery can lead to long-lasting and strong responses in patients with stage two or three colon cancer. The study, led by researchers at University College London (UCL) and University College London Hospitals (UCLH), found that just nine weeks of treatment with pembrolizumab before surgery resulted in lasting responses.

The trial, called NEOPRISM-CRC, included 32 patients with stage two or three colon cancer. These patients received up to nine weeks of pembrolizumab before undergoing surgery, instead of the usual approach of surgery followed by several months of chemotherapy. The results showed that 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery.

After 33 months of follow-up, none of the patients experienced a relapse. This is in contrast to standard care, where about 25% of patients treated with surgery followed by chemotherapy are expected to see their cancer return within three years.

The study also explored why this treatment worked so well and how to identify patients most likely to benefit. By analyzing blood samples, researchers developed personalized tests that can detect whether cancer DNA is still present in the bloodstream. These tests may allow doctors to determine early on whether the treatment has been successful.

Dr. Kai-Keen Shiu, Chief Investigator of the trial from UCL Cancer Institute and a Consultant Medical Oncologist at UCLH, said: 'Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging and strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers.'

Why It Matters

This breakthrough has the potential to save lives by providing a more effective treatment option for colon cancer patients. As colon cancer affects people of all ages, including those under 50, this news is especially important for Indian students who may be affected by this disease.

Key Facts

• The study found that immunotherapy before surgery can lead to long-lasting and strong responses in patients with stage two or three colon cancer.
• Patients who received immunotherapy stayed cancer-free for almost three years, compared to standard care where about 25% of patients experience a relapse within three years.
• The personalized blood tests developed by researchers may allow doctors to determine early on whether the treatment has been successful.

Key Terms

Immunotherapy

A type of cancer treatment that uses the body's immune system to fight cancer

Implications

This breakthrough has the potential to save lives by providing a more effective treatment option for colon cancer patients. As colon cancer affects people of all ages, including those under 50, this news is especially important for Indian students who may be affected by this disease.